Buscar
Celularity Inc
CELUAñadir a la lista de seguimiento
0.635USD
-0.045-6.57%
Cierre 07-31 16:00（ET）Cotizaciones retrasadas 15 min
17.93MCap. mercado
PérdidaP/E TTM
Más Datos de Celularity Inc Compañía
Celularity Inc. is a regenerative and cellular medicine company. The Company is developing and commercializing advanced biomaterial products and allogeneic, cryopreserved, placental-derived cell therapies, all derived from the postpartum placenta. Its therapeutic programs target aging-related diseases, including degenerative diseases, cancer, and immune disorders, using mesenchymal-like adherent stromal cells, T-cells engineered with CAR (CAR T-cells), and genetically modified and unmodified natural killer (NK) cells. It develops, manufactures and commercializes advanced biomaterial products derived from structural tissue components of the postpartum placental tissues, including the umbilical cord. Its advanced biomaterials include Celularity Tendon Wrap, FUSE Bone Void Filler and Celularity Placental Matrix. Its advanced biomaterial products include Biovance, Biovance 3L, CentaFlex, Interfyl and Rebound products.
Información de Celularity Inc
Símbolo de cotizaciónCELU
Nombre de la empresaCelularity Inc
Fecha de salida a bolsaMay 23, 2019
Director ejecutivoHariri (Robert J)
Número de empleados123
Tipo de seguridadOrdinary Share
Fin del año fiscalMay 23
Dirección170 Park Ave
CiudadFLORHAM PARK
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal07932
Teléfono19087682170
Sitio Webhttps://celularity.com/
Símbolo de cotizaciónCELU
Fecha de salida a bolsaMay 23, 2019
Director ejecutivoHariri (Robert J)
Ejecutivos de Celularity Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Robert J. (Bob) Hariri, M.D., Ph.D.
Dr. Robert J. (Bob) Hariri, M.D., Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
2.86M
+0.07%
Mr. Vincent Levien
Mr. Vincent Levien
Independent Director
Independent Director
157.55K
+18.31%
Dr. Peter H. Diamandis, M.D.
Dr. Peter H. Diamandis, M.D.
Independent Director
Independent Director
--
--
Ms. Diane L. Parks
Ms. Diane L. Parks
Independent Director
Independent Director
--
--
Mr. Stephen A. Brigido
Mr. Stephen A. Brigido
President - Degenerative Disease
President - Degenerative Disease
--
--
Mr. John R. Haines
Mr. John R. Haines
Senior Executive Vice President, Chief Administrative Officer, Corporate Secretary
Senior Executive Vice President, Chief Administrative Officer, Corporate Secretary
--
--
Dr. Shiu Fei (Geoffrey) Ling, M.D., Ph.D.
Dr. Shiu Fei (Geoffrey) Ling, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. Carlos Ramirez
Mr. Carlos Ramirez
Senior Vice President - Investor Relations
Senior Vice President - Investor Relations
--
--
Mr. Joseph Dossantos
Mr. Joseph Dossantos
Interim Chief Financial Officer
Interim Chief Financial Officer
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Robert J. (Bob) Hariri, M.D., Ph.D.
Dr. Robert J. (Bob) Hariri, M.D., Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
2.86M
+0.07%
Mr. Vincent Levien
Mr. Vincent Levien
Independent Director
Independent Director
157.55K
+18.31%
Dr. Peter H. Diamandis, M.D.
Dr. Peter H. Diamandis, M.D.
Independent Director
Independent Director
--
--
Ms. Diane L. Parks
Ms. Diane L. Parks
Independent Director
Independent Director
--
--
Mr. Stephen A. Brigido
Mr. Stephen A. Brigido
President - Degenerative Disease
President - Degenerative Disease
--
--
Mr. John R. Haines
Mr. John R. Haines
Senior Executive Vice President, Chief Administrative Officer, Corporate Secretary
Senior Executive Vice President, Chief Administrative Officer, Corporate Secretary
--
--
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Celularity Inc?
Los cinco principales accionistas de Celularity Inc son: Dr. Robert J. (Bob) Hariri, M.D., Ph.D.
¿Cuántas instituciones poseen acciones de Celularity Inc (CELU)?
A fecha de 2026Q1, 64 instituciones poseen acciones de Celularity Inc, con un valor de mercado combinado de aproximadamente 3.75M, lo que representa el 12.95% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en -258480.00.